{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:48:00Z","timestamp":1793353680661,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFD0500301"],"award-info":[{"award-number":["2016YFD0500301"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1200901"],"award-info":[{"award-number":["2016YFC1200901"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFC1200200"],"award-info":[{"award-number":["2016YFC1200200"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.vaccine.2019.02.063","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T08:37:33Z","timestamp":1551861453000},"page":"2122-2130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates"],"prefix":"10.1016","volume":"37","author":[{"given":"Ying","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-1146","authenticated-orcid":false,"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-1327","authenticated-orcid":false,"given":"Lianpan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorge F.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5963-1136","authenticated-orcid":false,"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.02.063_b0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","article-title":"Zika Virus. (I). Isolations and serological specificity","volume":"46","author":"Dick","year":"1952","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.02.063_b0010","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1056\/NEJMoa0805715","article-title":"Zika virus outbreak on Yap Island, Federated States of Micronesia \u2014 NEJM","volume":"360","author":"Duffy","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.02.063_b0015","doi-asserted-by":"crossref","first-page":"e0004636","DOI":"10.1371\/journal.pntd.0004636","article-title":"Zika Virus Outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects","volume":"10","author":"Brasil","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.02.063_b0020","article-title":"Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012\u20132014. Euro surveillance: bulletin Europeen sur les maladies transmissibles","volume":"19","author":"Roth","year":"2014","journal-title":"Eur Commun Dis Bull"},{"key":"10.1016\/j.vaccine.2019.02.063_b0025","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMc1603617","article-title":"Computed tomographic findings in microcephaly associated with Zika Virus","volume":"374","author":"Hazin","year":"2016","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2019.02.063_b0030","doi-asserted-by":"crossref","unstructured":"Besnard M, Lastere S, Teissier A, Caolormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro surveillance: Bull Eur sur les maladies Transm = Eur Commun Dis Bull 2014;19:13\u20136.","DOI":"10.2807\/1560-7917.ES2014.19.13.20751"},{"key":"10.1016\/j.vaccine.2019.02.063_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.11.016","article-title":"Zika virus causes testis damage and leads to male infertility in mice","volume":"167","author":"Ma","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.02.063_b0040","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3389\/fmicb.2017.01761","article-title":"Recent perspectives on genome, transmission, clinical manifestation, diagnosis, therapeutic strategies, vaccine developments, and challenges of Zika virus research","volume":"8","author":"Shankar","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.02.063_b0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/iub.1556","article-title":"Molecular basis of antibody-mediated neutralization and protection against flavivirus","volume":"68","author":"Dai","year":"2016","journal-title":"IUBMB Life"},{"key":"10.1016\/j.vaccine.2019.02.063_b0050","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1038\/s41598-017-15039-8","article-title":"A Zika vaccine targeting NS1 protein protects immunocompetent adult mice in a lethal challenge model","volume":"7","author":"Brault","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.02.063_b0055","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","article-title":"Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype","volume":"16","author":"Dowd","year":"2016","journal-title":"Cell Reports"},{"key":"10.1016\/j.vaccine.2019.02.063_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models","author":"Shan","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2019.02.063_b0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41467-018-02975-w","article-title":"Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2019.02.063_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization with a novel human type 5 Adenovirus-vectored vaccine expressing the premembrane and envelope proteins of Zika virus provides consistent and sterilizing protection in multiple immunocompetent and immunocompromised animal models","author":"Guo","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.02.063_b0075","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.063_b0080","article-title":"Modified mRNA vaccines protect against Zika virus infection","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2019.02.063_b0085","doi-asserted-by":"crossref","first-page":"e0005608","DOI":"10.1371\/journal.pntd.0005608","article-title":"Zika virus-like particle (VLP) based vaccine","volume":"11","author":"Boigard","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.02.063_b0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2019.02.063_b0095","article-title":"Zika virus vaccine development: progress in the face of new challenges","author":"Diamond","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2019.02.063_b0100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.virol.2005.02.014","article-title":"Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain","volume":"335","author":"Fang","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.02.063_b0105","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.vaccine.2017.04.059","article-title":"Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques","volume":"35","author":"Deng","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.063_b0110","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/mt.2013.122","article-title":"The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques","volume":"21","author":"Wen","year":"2013","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"10.1016\/j.vaccine.2019.02.063_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/vaccines6010008","article-title":"Challenges and achievements in prevention and treatment of smallpox","volume":"6","author":"Melamed","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2019.02.063_b0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14760584.2018.1522255","article-title":"Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines","volume":"17","author":"Prow","year":"2018","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.02.063_b0125","doi-asserted-by":"crossref","first-page":"e33392","DOI":"10.1371\/journal.pone.0033392","article-title":"A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.02.063_b0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1568005033481123","article-title":"Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery","volume":"3","author":"Sutter","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"key":"10.1016\/j.vaccine.2019.02.063_b0135","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.1995.tb44454.x","article-title":"Live attenuated vaccinia and other poxviruses as delivery systems: public health issues","volume":"754","author":"Perkus","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.vaccine.2019.02.063_b0140","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1016\/j.vaccine.2018.05.061","article-title":"The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens","volume":"36","author":"Chuai","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.063_b0145","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","article-title":"A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.02.063_b0150","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/CVI.05113-11","article-title":"Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-PreS1 and S-PreS1 plasmids","volume":"18","author":"Chen","year":"2011","journal-title":"Clin Vacc Immunol: CVI"},{"key":"10.1016\/j.vaccine.2019.02.063_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01722-17","article-title":"Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against Zika virus infection and testis damage","volume":"92","author":"Xu","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.02.063_b0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00900-17","article-title":"CD8+ T cell immune response in immunocompetent mice during Zika virus infection","author":"Huang","year":"2017","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2019.02.063_b0165","doi-asserted-by":"crossref","first-page":"E631","DOI":"10.3390\/v10110631","article-title":"Recent advances in Zika virus vaccines","volume":"10","author":"Garg","year":"2018","journal-title":"Viruses"},{"issue":"25","key":"10.1016\/j.vaccine.2019.02.063_b0170","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.vaccine.2014.03.093","article-title":"An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara","volume":"32","author":"Quinan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.02.063_b0175","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1016\/j.vaccine.2016.10.058","article-title":"A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis","author":"Quinan","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.02.063_b0180","doi-asserted-by":"crossref","first-page":"e0170462","DOI":"10.1371\/journal.pone.0170462","article-title":"Comprehensive annotation of mature peptides and genotypes for Zika Virus","volume":"12","author":"Sun","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.02.063_b0185","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.02.063_b0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.chom.2016.03.010","article-title":"A mouse model of Zika virus pathogenesis","volume":"19","author":"Lazear","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.02.063_b0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-018-0072-6","article-title":"Incorporation of NS1 and prM\/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein","volume":"3","author":"Liu","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2019.02.063_b0200","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-017-01669-z","article-title":"Dengue virus-reactive CD8+ T cells mediate cross-protection against subsequent Zika virus challenge","volume":"8","author":"Wen","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2019.02.063_b0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni.3515","article-title":"Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus","volume":"17","author":"Dejnirattisai","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.02.063_b0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19302701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:30:22Z","timestamp":1759401022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19302701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0264410X19302701"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.02.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}